Know Cancer

or
forgot password

Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Patients With Renal Cell Carcinoma Under Tyrosin Kinase Inhibitor Therapy


N/A
18 Years
N/A
Open (Enrolling)
Both
Renal Cell Carcinoma

Thank you

Trial Information

Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Patients With Renal Cell Carcinoma Under Tyrosin Kinase Inhibitor Therapy


Inclusion Criteria:



- Male and female patients with histologically confirmed renal cell carcinoma

- Prior to tyrosine kinase inhibitor therapy

- Age: at least 18 yrs

- Body mass index (BMI): at least 18 kg/m2

- ECOG performance status: at most 2

- Must be able to meet the requirements of the study protocol

Exclusion Criteria:

- Acute infectious diseases

- No ambulatory ability

- Severe neurological disorders

- Severe cardiovascular diseases

- Severe pulmonary insufficiency

- Severe renal insufficiency

- Other current tumor diseases

- Conditions rendering compliance impossible

- Participation in regular strength training

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change in cancer related fatigue

Outcome Description:

Assessed via the Multidimensional Fatigue Inventory (MFI).

Outcome Time Frame:

From baseline to the 6th and 12th week of training.

Safety Issue:

No

Principal Investigator

Carsten Grüllich, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany

Authority:

Germany: Ethics Committee of the Medical Faculty Heidelberg

Study ID:

S-154/2012

NCT ID:

NCT01645150

Start Date:

May 2012

Completion Date:

December 2014

Related Keywords:

  • Renal Cell Carcinoma
  • physical activity
  • exercise
  • training
  • fatigue
  • cancer
  • renal cell carcinoma
  • tyrosine kinase inhibitor
  • Carcinoma
  • Carcinoma, Renal Cell
  • Fatigue

Name

Location